Jury Rules in Favor of Allergan, Inc.; Judge Dismisses Remaining Claims
Treatment Not Related to Plaintiff's Claims Allergan, Inc.
(NYSE:AGN) announced today that the jury in the Irena Medavoy vs. Arnold Klein, M.D., and Allergan, Inc. lawsuit found that Allergan's product BOTOX(R) (botulinum toxin type A) was not responsible for the conditions Irena Medavoy alleged she suffered following her treatment with BOTOX(R) for migraine. The jury trial, which concluded today, was tried in the Superior Court of California, County of Los Angeles, Central District.
"The verdict is not merely a vindication of Allergan and BOTOX(R), it is a victory for good science and medicine," said Douglas S. Ingram, Executive Vice President, General Counsel and Secretary at Allergan. "We are proud that BOTOX(R), one of the most versatile medicines in the world, has brought relief and better quality of life to millions of people suffering from serious debilitating conditions."
The Judge also dismissed the claims against both Allergan and Dr. Klein pertaining to the California Business and Professions Code.
The safety and efficacy of BOTOX(R) have been established in double-blind, placebo-controlled clinical trials involving over 10,000 patients, as well as in open-label studies and extensive clinical practice involving millions of patients over the last 15 years. With more than 1,800 publications in scientific and medical journals, botulinum toxin type A is one of the most widely researched medicines in the world. BOTOX(R) has been approved by regulatory authorities for 20 different indications in more than 70 countries. As with any medicine, patients should always consult with their physician about the associated benefits and risks of treatment.
About Allergan, Inc.
Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator, skin care and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients' lives. --30--ST/np*
Allergan Jim Hindman (Investors), 714-246-4636
Joann Bradley (Investors), 714-246-4766
Caroline Van Hove (Media), 714-246-5134
Stephanie Fagan (Media), 714-246-5232
INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL
PRODUCT SOURCE: Allergan